DYN

Dyne Therapeutics Inc

Add to Watchlist

Advanced Chart

9.250

-0.06(-0.644%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.250

Open

9.250

VWAP

Vol

Mkt Cap

1.28B

Low

9.250

Amount

EV/EBITDA(TTM)

Total Shares

99.46M

698.52M

EV/OCF(TTM)

P/S(TTM)

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.936

+6.39%

-0.946

-1.47%

-0.933

+33.34%

Estimates Revision

Stock Price

Go Down

-20.56%

In Past 3 Month

14 Analyst Rating

305.84% Upside

Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 37.54 USD with a low forecast of 9.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

2 Hold

0 Sell

Strong Buy

305.84% Upside

Current: 9.250

Low

9.00

Averages

37.54

High

66.00

305.84% Upside

Current: 9.250

Low

9.00

Averages

37.54

High

66.00

Evercore ISI

Gavin Clark-Gartner

Outperform

downgrade

$46 -> $41

2025-07-11

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$46 -> $41

2025-07-11

downgrade

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

JonesResearch

NULL -> Buy

initiated

$30

2025-06-25

Reason

JonesResearch

Price Target

$30

2025-06-25

initiated

NULL -> Buy

Reason

Bernstein

Market Perform

initiated

$13

2025-06-24

Reason

Bernstein

Price Target

$13

2025-06-24

initiated

Market Perform

Reason

Baird

Outperform -> NULL

downgrade

$46 -> $32

2025-06-19

Reason

Baird

Price Target

$46 -> $32

2025-06-19

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Dyne Therapeutics to $32 from $46 and keeps an Outperform rating on the shares. The firm updated its model following the swapping of the DYNE-101 endpoint from splicing to vHOT.

Raymond James

Martin Auster

Outperform

initiated

$37

2025-06-10

Reason

Raymond James

Martin Auster

Price Target

$37

2025-06-10

initiated

Outperform

Reason

Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added.

Oppenheimer

Andreas Argyrides

Outperform

downgrade

$60 -> $34

2025-06-02

Reason

Oppenheimer

Andreas Argyrides

Price Target

$60 -> $34

2025-06-02

downgrade

Outperform

Reason

Oppenheimer analyst Andreas Argyrides assumed coverage of Dyne Therapeutics with an Outperform rating with a price target of $34, down from $60, after the company reported its Q1 and highlighted progress across its DM1 and Duchenne muscular dystrophy programs. In the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1, following the recent compelling data, the firm is encouraged to see the registrational expansion cohort staying on track for readout in the first half of 2026. Management highlighted its recent participation in a CDER Type C held in May 2025 for DYNE-101 in DM1, and plans to provide a regulatory update following receipt of meeting minutes. In the Phase 1/2 DELIVER trial of DYNE-251 in DMD, the registrational expansion cohort readout remains expected in late 2025.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dyne Therapeutics Inc (DYN.O) is -2.66, compared to its 5-year average forward P/E of -5.68. For a more detailed relative valuation and DCF analysis to assess Dyne Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.68

Current PE

-2.66

Overvalued PE

-2.30

Undervalued PE

-9.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.92

Current EV/EBITDA

-1.66

Overvalued EV/EBITDA

-0.70

Undervalued EV/EBITDA

-7.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00